26 June
2024
Avacta Group
plc
("Avacta"
or the "Group" or the "Company")
Result of Annual General
Meeting
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted cancer treatments
and powerful diagnostics, is pleased to
announce that all resolutions have been duly passed (with the
exception of Resolution 6 which was not put to the meeting) by
shareholders at the Annual General Meeting held
today.
The full text of each resolution is
set out in the Notice of Annual General Meeting, which is available
under the Investor Resources section of the Company's
website https://avacta.com/investors/investor-resources/.
All presentation materials available to
shareholders, including slide decks and a video presentation by
Chris Coughlin, will also be posted at the same link as above by
the end of the day.
-Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Christina
Coughlin, CEO
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44 (0) 1904 21 7070
www.avacta.com
|
|
|
|
|
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
www.peelhunt.com
|
|
ICR
Consilium
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer
drugs.
Avacta Diagnostics focuses on
supporting healthcare professionals and broadening access to
diagnostics.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown an improvement in safety and tolerability
in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple
patients.
To register for news alerts by email
go to www.avacta.com/investor-news-email-alerts